B2 integrin–derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis

Blood

Volumn 121, Issue 19, 2013, Pages 3889-3899

  Oellerich, Thomas ^a   Oellerich, Mark F ^b   Engelke, Michael ^c   Münch, Silvia ^a   Mohr, Sebastian ^a   Nimz, Marika ^a,d   Hsiao, He Hsuan ^e   Corso, Jasmin ^e   Zhang, Jing ^a   Bohnenberger, Hanibal ^a   Berg, Tobias ^a   Rieger, Michael A ^f   Wienands, Jürgen ^c   Bug, Gesine ^a   Brandts, Christian ^a   Urlaub, Henning ^e,g   Serve, Hubert ^a,d  

^a Oncological Center   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^f INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^g UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTEGRIN; ALPHA TUBULIN; BETA TUBULIN; CBL PROTEIN; CD11B ANTIGEN; CD18 ANTIGEN; CD34 ANTIGEN; CELL SURFACE RECEPTOR; DYNEIN 1 HEAVY CHAIN 1; DYNEIN 1 INTERMEDIATE CHAIN 2; DYNEIN ADENOSINE TRIPHOSPHATASE; FC GAMMA RECEPTOR I; FC RECEPTOR; MULTIPROTEIN COMPLEX; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN 14 3 3; PROTEIN KINASE SYK; PROTEIN P85; PROTEOME; STAT3 PROTEIN; STAT5 PROTEIN; STAT5A PROTEIN; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE; STAT PROTEIN; STAT3 PROTEIN, HUMAN;

ACUTE MYELOID LEUKEMIA CELL LINE; ARTICLE; BONE MARROW CELL; CANCER PATIENT; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOID CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SIGNAL TRANSDUCTION; STEM CELL NICHE; ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SEQUENCE; BIOLOGICAL MODEL; DRUG ANTAGONISM; GENETICS; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

AMINO ACID SEQUENCE; ANTIGENS, CD18; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID, ACUTE; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

MLCS; MLOWN;

EID: 84879996107     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-457887     Document Type: Article

References (47)

1. Choudhary C, Brandts C, Schwable J, et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood. 2007;110(1):370-374.
2. Pitini V, Arrigo C, Altavilla G. Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3645-3646.
3. Chan G, Pilichowska M. Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer. Blood. 2007;110(3):1079-1080.
4. Hahn CK, Berchuck JE, Ross KN, et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 2009;16(4):281-294.
5. Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010; 10(6):387-402.
6. Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111(4):2230-2237.
7. Coopman PJ, Do MT, Barth M, et al. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature. 2000; 406(6797):742-747.
8. Cheng S, Coffey G, Zhang XH, et al. SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood. 2011;118(24): 6342-6352.
9. Goodman PA, Wood CM, Vassilev A, Mao C, Uckun FM. Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia. Oncogene. 2001;20(30): 3969-3978.
10. Kulathu Y, Grothe G, Reth M. Autoinhibition and adapter function of Syk. Immunol Rev. 2009; 232(1):286-299.
11. Sada K, Takano T, Yanagi S, Yamamura H. Structure and function of Syk protein-tyrosine kinase. J Biochem. 2001;130(2):177-186.
12. Kurosaki T, Shinohara H, Baba Y. B cell signaling and fate decision. Annu Rev Immunol. 2010;28: 21-55.
13. Humphrey MB, Lanier LL, Nakamura MC. Role of ITAM-containing adapter proteins and their receptors in the immune system and bone. Immunol Rev. 2005;208(1):50-65.
14. Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R, Finke J. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood. 1996;88(3):809-816.
15. Spiekermann K, Biethahn S, Wilde S, Hiddemann W, Alves F. Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol. 2001;67(2):63-71.
16. Heuser M, Sly LM, Argiropoulos B, et al. Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. Blood. 2009;114(19):3983-3993.
17. Mizuki M, Schwable J, Steur C, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood. 2003;101(8):3164-3173.
18. Pallis M, Seedhouse C, Grundy M, Russell N. Flow cytometric measurement of phosphorylated STAT5 in AML: lack of specific association with FLT3 internal tandem duplications. Leuk Res. 2003;27(9):803-805.
19. Oellerich T, Grønborg M, Neumann K, Hsiao HH, Urlaub H, Wienands J. SLP-65 phosphorylation dynamics reveals a functional basis for signal integration by receptor-proximal adaptor proteins. Mol Cell Proteomics. 2009;8(7):1738-1750.
20. Melendez AJ, Gillooly DJ, Harnett MM, Allen JM. Aggregation of the human high affinity immunoglobulin G receptor (FcgammaRI) activates both tyrosine kinase and G protein-coupled phosphoinositide 3-kinase isoforms. Proc Natl Acad Sci USA. 1998;95(5):2169-2174.
21. Xue ZH, Zhao CQ, Chua GL, Tan SW, Tang XY, Wong SC, Tan SM. Integrin alphaMbeta2 clustering triggers phosphorylation and activation of protein kinase C delta that regulates transcription factor Foxp1 expression in monocytes. J Immunol. 2010;184(7):3697-3709.
22. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr. Stat3 as an oncogene. Cell. 1999;98(3):295-303.
23. Moriggl R, Sexl V, Kenner L, et al. Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell. 2005;7(1):87-99.
24. Oellerich T, Bremes V, Neumann K, et al. The B-cell antigen receptor signals through a preformed transducer module of SLP65 and CIN85. EMBO J. 2011;30(17):3620-3634.
25. Selbach M, Mann M. Protein interaction screening by quantitative immunoprecipitation combined with knockdown (QUICK). Nat Methods. 2006; 3(12):981-983.
26. Bohnenberger H, Oellerich T, Engelke M, Hsiao HH, Urlaub H, Wienands J. Complex phosphorylation dynamics control the composition of the Syk interactome in B cells. Eur J Immunol. 2011;41(6): 1550-1562.
27. Schnyder T, Castello A, Feest C, et al. B cell receptor-mediated antigen gathering requires ubiquitin ligase Cbl and adaptors Grb2 and Dok-3 to recruit dynein to the signaling microcluster. Immunity. 2011;34(6):905-918.
28. Spiekermann K, Pau M, Schwab R, Schmieja K, Franzrahe S, Hiddemann W. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol. 2002;30(3):262-271.
29. Jakus Z, Fodor S, Abram CL, Lowell CA, Mócsai A. Immunoreceptor-like signaling by beta 2 and beta 3 integrins. Trends Cell Biol. 2007;17(10):493-501.
30. Stirewalt DL, Meshinchi S, Radich JP. Molecular targets in acute myelogenous leukemia. Blood Rev. 2003;17(1):15-23.
31. Bradshaw JM. The Src, Syk, and Tec family kinases: distinct types of molecular switches. Cell Signal. 2010;22(8):1175-1184.
32. Mócsai A, Abram CL, Jakus Z, Hu Y, Lanier LL, Lowell CA. Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs. Nat Immunol. 2006;7(12):1326-1333.
33. Weir EG, Ali Ansari-Lari M, Batista DA, et al. Acute bilineal leukemia: a rare disease with poor outcome. LeukemiaK. 2007;21(11):2264-2270.
34. Schepers H, van Gosliga D, Wierenga AT, Eggen BJ, Schuringa JJ, Vellenga E. STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. Blood. 2007;110(8):2880-2888.
35. Choudhary C, Olsen JV, Brandts C, et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell. 2009;36(2):326-339.
36. Agrawal S, Koschmieder S, Bäumer N, Reddy NG, Berdel WE, Müller-Tidow C, Serve H. Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation. Leukemia. 2008;22(1):78-86.
37. Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011; 117(21):5701-5709.
38. Uckun FM, Qazi S, Ma H, Tuel-Ahlgren L, Ozer Z. STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proc Natl Acad Sci USA. 2010; 107(7):2902-2907.
39. van der Poel CE, Spaapen RM, van de Winkel JG, Leusen JH. Functional characteristics of the high affinity IgG receptor, FcgRI. J Immunol. 2011; 186(5):2699-2704.
40. Parmar A, Marz S, Rushton S, et al. Stromal niche cells protect early leukemic FLT3-ITD1 progenitor cells against first-generation FLT3 tyrosine kinase inhibitors. Cancer Res. 2011;71(13):4696-4706.
41. Weisberg E, Liu Q, Nelson E, et al. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/ multi-targeted inhibitors, and JAK inhibitors. Leukemia. 2012;26(10): 2233-2244.
42. Graf M, Reif S, Kröll T, Hecht K, Nuessler V, Schmetzer H. Expression of MAC-1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis. Am J Hematol. 2006; 81(4):227-235.
43. Dunphy CH, Tang W. The value of CD64 expression in distinguishing acute myeloid leukemia with monocytic differentiation from other subtypes of acute myeloid leukemia: a flow cytometric analysis of 64 cases. Arch Pathol Lab Med. 2007;131(5):748-754.
44. Paietta E, Andersen J, Yunis J, et al; Eastern Cooperative Oncology Group. Acute myeloid leukaemia expressing the leucocyte integrin CD11b-a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis. Br J Haematol. 1998;100(2):265-272.
45. Yankee TM, Keshvara LM, Sawasdikosol S, Harrison ML, Geahlen RL. Inhibition of signaling through the B cell antigen receptor by the protooncogene product, c-Cbl, requires Syk tyrosine 317 and the c-Cbl phosphotyrosine-binding domain. J Immunol. 1999;163(11): 5827-5835.
46. Deckert M, Tartare-Deckert S, Couture C, Mustelin T, Altman A. Functional and physical interactions of Syk family kinases with the Vav proto-oncogene product. Immunity. 1996;5(6): 591-604.
47. Moon KD, Post CB, Durden DL, Zhou Q, De P, Harrison ML, Geahlen RL. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. J Biol Chem. 2005;280(2):1543-1551.